Imaavy Injection, Solution, Concentrate
FDA Recall NDC 57894-800

Latest: Class II · Status: Ongoing · Initiated Sep 23, 2026 · 1 enforcement report

Active & Historical Enforcement Reports

The FDA has identified 1 recorded enforcement report(s) associated with Imaavy (NDC 57894-800). A significant event, classified as Class II, was initiated on Sep 23, 2026 by Janssen Biotech, Inc.. The reported reason for this action was: "Presence of particulate matter."

This recall is currently ONGOING. Healthcare providers and patients are advised to check their inventory immediately against the affected codes provided below.

Reported Recall Events

September 2026 Class II Recall: Presence of particulate matter.

Recall Number
Class II Ongoing
Reason for Recall
Presence of particulate matter.
Initiated
Sep 23, 2026
Reported
Oct 14, 2026
Quantity
49 vials

Recall Profile & Regulatory Data

Event ID
99972
Classification
Class II
Enforcement Status
Ongoing
Recalling Firm
J&J INNOVATIVE MEDICINE
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
OH
Product Description
IMAAVY (nipocalimab-aahu) Injection, 300 mg /1.62 mL (185 mg/mL) per single-dose vial, For Intravenous Infusion After Dilution, Rx only, Manufactured by: Janssen Biotech, Inc., Horsham, PA 19044. NDC: 57894-800-01
Batch or Lot Expiration Information
Lot# Lot JNYJ1208; Exp. 10/30/2027
Affected Packages Involved in this Recall
57894-801-01Imaavy
57894-800-01Imaavy

About FDA Recall Enforcement Reports

FDA recall data documents classified recall actions associated with a product. Most recalls are limited to specific lots, batches, or package configurations rather than every unit of a drug.

If a recall is listed for an NDC, review the affected lot information and package details carefully. Patients and healthcare professionals should confirm whether a specific product in hand matches the lot or package information before assuming it is affected.